Results 1 to 10 of about 145 (70)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Marrakech cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
El Ansari Nawal
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Qatar cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Mohamed Hasan Daghash, Jabbar Mubarak Raja, Mohamed Milad   +2 more
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Mustafa Al Abousi
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sreejith N Kumar, Tom Babu, V M Haridas
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Uday Phadke, Sunil Gupta, Vaishali Deshmukh   +2 more
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Zayed Atef, Abdulkareem Al-Khawlany, Abdalla A Gunaid   +2 more
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from North and the oriental region of Morocco cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66 726) in routine clinical care ...
Othmane Laaribi
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sanjay Kalra, Lokesh Garg, Sandeep Suri, Sameer Aggarwal   +3 more
doaj   +2 more sources

Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Issam M Hajjaji, Ibrahim Sherif, Aisha Elazrag, Suhair Jaber, Praful N Chakkarwar, Salem Eltabal   +5 more
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Alaa Daban, Hussain Haji Ali
doaj   +2 more sources